Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016
SKU ID :GMD-10269358 | Published Date: 10-Aug-2016 | No. of pages: 442Description
TOC
Table of Contents
Table of Contents 2
Introduction 7
Crohn's Disease (Regional Enteritis) Overview 8
Therapeutics Development 9
Crohn's Disease (Regional Enteritis) - Therapeutics under Development by Companies 11
Crohn's Disease (Regional Enteritis) - Therapeutics under Investigation by Universities/Institutes 19
Crohn's Disease (Regional Enteritis) - Pipeline Products Glance 20
Crohn's Disease (Regional Enteritis) - Products under Development by Companies 24
Crohn's Disease (Regional Enteritis) - Products under Investigation by Universities/Institutes 33
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development 34
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment 113
Drug Profiles 136
Crohn's Disease (Regional Enteritis) - Dormant Projects 400
Crohn's Disease (Regional Enteritis) - Discontinued Products 412
Crohn's Disease (Regional Enteritis) - Product Development Milestones 414
Appendix 426
Tables & Figures
Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016’, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)
- The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects
- The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipelineTable of Contents
Table of Contents 2
Introduction 7
Crohn's Disease (Regional Enteritis) Overview 8
Therapeutics Development 9
Crohn's Disease (Regional Enteritis) - Therapeutics under Development by Companies 11
Crohn's Disease (Regional Enteritis) - Therapeutics under Investigation by Universities/Institutes 19
Crohn's Disease (Regional Enteritis) - Pipeline Products Glance 20
Crohn's Disease (Regional Enteritis) - Products under Development by Companies 24
Crohn's Disease (Regional Enteritis) - Products under Investigation by Universities/Institutes 33
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development 34
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment 113
Drug Profiles 136
Crohn's Disease (Regional Enteritis) - Dormant Projects 400
Crohn's Disease (Regional Enteritis) - Discontinued Products 412
Crohn's Disease (Regional Enteritis) - Product Development Milestones 414
Appendix 426
Companies
4D Pharma Plc
4SC AG
AB Science SA
AbbVie Inc
Alfa Wassermann S.p.A
Alteogen Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
ARA Healthcare Pvt. Ltd.
Arena Pharmaceuticals, Inc.
Astellas Pharma Inc.
BioLingus AG
Bionovis SA
BioTherapeutics Inc.
Calypso Biotech SA
Celgene Corporation
ChemoCentryx, Inc.
ChironWells GmbH
CLL Pharma
Coherus BioSciences, Inc.
Commence Bio, Inc.
Daiichi Sankyo Company, Limited
DBV Technologies S.A.
Eisai Co., Ltd.
Eli Lilly and Company
Enterome Bioscience SA
Enzo Biochem, Inc.
Epirus Biopharmaceuticals, Inc.
Ferring International Center S.A.
Galapagos NV
Genentech, Inc.
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
iCo Therapeutics Inc.
Idera Pharmaceuticals, Inc.
Immune Response BioPharma, Inc.
Innovent Biologics, Inc.
Johnson & Johnson
Jyant Technologies, Inc.
Kang Stem Biotech Co., Ltd.
KPI Therapeutics, Inc.
Kyorin Pharmaceutical Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Neovacs SA
Oncobiologics, Inc.
Oncodesign SA
OSE Immunotherapeutics
Pfenex Inc.
Pfizer Inc.
Pieris Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Protalix BioTherapeutics, Inc.
Qu Biologics Inc.
Re-Pharm Limited
RedHill Biopharma Ltd.
Sandoz International GmbH
SATT North SAS
Second Genome, Inc.
Selexys Pharmaceuticals Corporation
Selvita S.A.
Shire Plc
Sigmoid Pharma Limited
Soligenix, Inc.
Stelic Institute & Co., Inc.
Sylentis S.A.U.
TaiwanJ Pharmaceuticals Co., Ltd.
Takeda Pharmaceutical Company Limited
Therapeutic Proteins International, LLC
Tiziana Life Sciences Plc
Trino Therapeutics Limited
TxCell SA
Ventria Bioscience
Virobay Inc.
Xbrane Biopharma AB
- PRICE
-
$2000$6000